Showing results (11-20 of 496) with videos related to
Sort By:
Pageof 50
The Biochemical Journal|November 4, 2008
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitizationElizabeth Iorns, Christopher J Lord, Alan AshworthClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Targeting the double-strand DNA break repair pathway as a therapeutic strategyChristopher J Lord, Michelle D Garrett, Alan AshworthCancer Cell|September 10, 2014
DAISY: picking synthetic lethals from cancer genomesColm J Ryan, Christopher J Lord, Alan AshworthCurrent Opinion in Genetics & Development|March 18, 2008
DNA repair deficiency as a therapeutic target in cancerSarah A Martin, Christopher J Lord, Alan AshworthNature Reviews. Drug Discovery|December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP familyJenna L Riffell, Christopher J Lord, Alan AshworthCancer Discovery|November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapyFarah L Rehman, Christopher J Lord, Alan AshworthClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathwaySarah A Martin, Christopher J Lord, Alan AshworthNature Reviews. Clinical Oncology|October 20, 2010
Synthetic lethal approaches to breast cancer therapyFarah L Rehman, Christopher J Lord, Alan AshworthNature Reviews. Drug Discovery|June 30, 2007
Utilizing RNA interference to enhance cancer drug discoveryElizabeth Iorns, Christopher J Lord, Nicholas Turner, et al.Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan AshworthPageof 50